We claim:

5

20

- 1. A method of treating a subject suffering from a lysosomal storage disorder other than Fabry Disease caused by a deficiency of a specific protein comprising:
 - (a) producing said protein or an active fragment thereof in an insect cell culture, and(b) administering a therapeutically effective amount of said protein to said subject.
- The method of claim 1 wherein said lysosomal storage disorder is selected from the group consisting of Pompe Disease, GM1 gangliosidosis, Tay-Sachs disease, GM2 gangliosialidosis: AB Variant, Sandhoff Disease, Gaucher Disease, Krabbe Disease, Niemann-Pick Types A-D, Farber Disease, Wolman Disease, Cholesterol Ester Storage Disease, Hurler Syndrome, Scheie Syndrome, Hurler-Scheie, Hunter Syndrome, Sanfilippo A-D, Morquio A-B, Maroteaux-Lamy, Sly Syndrome, Metachromatic Leukodystrophy, Multiple Sulfatase Deficiency, Sialidosis, I-Cell Disease, Pseudo-Hurler Polydistrophy, Mucolipidosis IV, α-Mannosidosis, β-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Galactosialidosis, Schindler Disease, Cystinosis, Salla Disease, Infantile Sialic Acid Storage Disorder, Batten Disease, Infantile Neuronal Ceroid Lipofuscinosis, and Prosaposin.

The method of claim 1 wherein said protein is selected from the group consisting of acid α-1,4 glucosidase, acid α-1,6 glucosidase, β-galactosidase, β-hexosaminidase A, GM₂ Activator Protein, β-hexosaminidase A, β-hexosaminidase B, glucocerebrosidase, β-glucosidase, galactosylcerebrosidase, acid sphingomyelinase, acid ceramidase, acid lipase, α-L-iduronidase, iduronate sulfatase, α-N-acetylglucosaminidase, acetyl-CoA-glucosaminide acetyltransferase, N-acetylglucosamine-6-sulfatase, galactosamine-6-sulfatase, arylsuylfatase B, β-glucuronidase, arylsulfatase A, arylsulfatase C, α-Neuraminidase, UDP GlcNAc:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, neuraminidase, α-mannosidase, β-mannosidase, α-L-fucosidase, N-aspartyl-β-

glucosaminidase, protective protein/cathepsin A (PPCA), α-N-acetyl-

galactosaminidase, cystine transport protein, sialic acid transport protein, palmitoylprotein thioesterase, and Saposins A-D.

- 4. The method of claim 1 wherein said protein is produced in an insect cell culture using a baculovirus expression system.
- 5. The method of claim 1 wherein said insect cell culture is derived from the species *Spodoptera frugiperda*.
- 10 6. The method of claim 5 wherein said insect cell culture is an Sf9 cell culture.
 - 7. A method of treating a subject with a protein other than α -galactosidase that is therapeutically active when present in a macrophage comprising:
- 15 (a) producing said protein in an insect cell culture; and

5

20

25

- (b) administering a therapeutically effective amount of said protein to said subject.
- 8. A pharmaceutical composition comprising a protein useful for treating a lysosomal storage disorder other than Fabry disease that is selectively imported into macrophages when administered to a subject and a pharmaceutically acceptable carrier, wherein said protein is produced in an insect cell culture.
- 9. The composition of claim 8 wherein said lysosomal storage disorder is selected from the group consisting of Pompe Disease, GM1 gangliosidosis, Tay-Sachs disease, GM2 gangliosialidosis: AB Variant, Sandhoff Disease, Gaucher Disease, Krabbe
- Disease, Niemann-Pick Types A-D, Farber Disease, Wolman Disease, Cholesterol Ester Storage Disease, Hurler Syndrome, Scheie Syndrome, Hurler-Scheie, Hunter Syndrome, Sanfilippo A-D, Morquio A-B, Maroteaux-Lamy, Sly Syndrome, Metachromatic Leukodystrophy, Multiple Sulfatase Deficiency, Sialidosis, I-Cell
 - Disease, Pseudo-Hurler Polydistrophy, Mucolipidosis IV, α-Mannosidosis, β-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Galactosialidosis, Schindler

Disease, Cystinosis, Salla Disease, Infantile Sialic Acid Storage Disorder, Batten Disease, Infantile Neuronal Ceroid Lipofuscinosis, and Prosaposin.

- 10. The composition of claim 8 wherein said protein is selected from the group consisting 5 of acid α -1,4 glucosidase, acid α -1,6 glucosidase, β -galactosidase, β -hexosaminidase A, GM_2 Activator Protein, β -hexosaminidase A, β -hexosaminidase B, glucocerebrosidase, β-glucosidase, galactosylcerebrosidase, acid sphingomyelinase, acid ceramidase, acid lipase, α -L-iduronidase, iduronate sulfatase, α -Nacetylglucosaminidase, acetyl-CoA-glucosaminide acetyltransferase, N-201 10 acetylglucosamine-6-sulfatase, galactosamine-6-sulfatase, arylsuylfatase B, βglucuronidase, arylsulfatase A, arylsulfatase C, α-Neuraminidase, UDP GlcNAc:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, neuraminidase, α -mannosidase, β -mannosidase, α -L-fucosidase, N-aspartyl- β glucosaminidase, protective protein/cathepsin A (PPCA), α-N-acetyl-15 galactosaminidase, cystine transport protein, sialic acid transport protein, palmitoylprotein thioesterase, and Saposins A-D.
 - 11. The composition of claim 8 wherein said insect cell culture comprises cells derived from the species selected from the group consisting of *Spodoptera frugiperda* and *Tricoplusia ni*.

20

30

- 12. The composition of claim 11 wherein said cells are Spodoptera frugiperda Sf9 cells.
- 13. The composition of claim 8 wherein said protein is produced in the cell culture usinga baculovirus expression system.
 - 14. A method for producing a protein associated with a lysosomal storage disorder other than α-galactosidase, protective protein/cathepsin A (PPCA), cathepsin B, cathepsin S, β-galactosidase, β-hexosaminidase B, neuraminidase, lysosomal acid lipase, prorenin, glucocerebrosidase and lysosomal acid alpha-glucosidase in a form that is

selectively imported into macrophages when administered to a subject comprising producing said protein in an insect cell culture.

15. The method of claim 14 wherein said lysosomal storage disorder is selected from the
group consisting of GM2 gangliosialidosis: AB Variant, Sandhoff Disease, Krabbe Disease, Niemann-Pick Types A-D, Farber Disease, Hurler Syndrome, Scheie Syndrome, Hurler-Scheie, Hunter Syndrome, Sanfilippo A-D, Morquio A, Maroteaux-Lamy, Sly Syndrome, Metachromatic Leukodystrophy, Multiple Sulfatase Deficiency, I-Cell Disease, Pseudo-Hurler Polydistrophy, Mucolipidosis IV, α-Mannosidosis, β-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Schindler Disease, Cystinosis, Salla Disease, Infantile Sialic Acid Storage Disorder, Batten

Disease, Infantile Neuronal Ceroid Lipofuscinosis, and Prosaposin.

- 16. The method of claim 14 wherein said protein is selected from the group consisting of GM₂ Activator Protein, β-hexosaminidase A, β-hexosaminidase B, galactosylcerebrosidase, acid sphingomyelinase, acid ceramidase, α-L-iduronidase, iduronate sulfatase, α-N-acetylglucosaminidase, acetyl-CoA-glucosaminide acetyltransferase, N-acetylglucosamine-6-sulfatase, galactosamine-6-sulfatase, arylsuylfatase B, β-glucuronidase, arylsulfatase A, arylsulfatase C, UDP GlcNAc:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, neuraminidase, α-mannosidase, β-mannosidase, α-L-fucosidase, N-aspartyl-β-glucosaminidase, α-N-acetyl-galactosaminidase, cystine transport protein, sialic acid transport protein, palmitoyl-protein thioesterase, and Saposins A-D,
- 25 17. A protein-conjugate complex that is selectively imported into macrophages when administered to a subject wherein the protein component of said protein-conjugate complex is produced in an insect cell culture.
- 18. A method for increasing the ability of a cell to uptake a protein produced in an insect cell culture comprising causing said cell to express a mannose receptor on its membrane.

- 19. A system for targeting a protein to a desired cell comprising:
 - (a) causing said cell to express a mannose receptor on its membrane;
- 5 (b) producing said protein in an insect cell culture; and
 - (c) contacting said protein with said cell.

10

20. In a method for purifying a protein produced in an insect cell culture using a Concanavalin A-Sepharose column, an improvement comprising the use of a buffer containing methyl-α-D-manno-pyranoside to elute said protein from said Concanavalin A-Sepharose column.